Cerebral Degeneration disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: CRB033 MIFTS: 42	Cerebral Degeneration Categories: Neuronal diseases
Genes Tissues Related diseases Publications Pathways Drugs Expand all tables

Sources

Aliases & Classifications for Cerebral Degeneration

MalaCards integrated aliases for Cerebral Degeneration:

Name: Cerebral Degeneration ¹² ¹⁵

Degenerative Brain Disorder ⁷²

Brain Degeneration ¹²

Classifications:

MalaCards categories:
Anatomical: Neuronal diseases

See all MalaCards categories (disease lists)

External Ids:

Disease Ontology ¹² DOID:1443

ICD9CM ³⁵ 331.9

SNOMED-CT ⁶⁸ 52522001 73768007

UMLS ⁷² C0154671

Sources

Summaries for Cerebral Degeneration

Disease Ontology : ¹² A brain disease that is characterized by loss of structure or function of neurons, including death of neurons and loss of brain tissue.

MalaCards based summary : Cerebral Degeneration, also known as degenerative brain disorder, is related to leukodystrophy and aceruloplasminemia. An important gene associated with Cerebral Degeneration is NOTCH3 (Notch Receptor 3), and among its related pathways/superpathways is Peroxisome. The drugs Galantamine and Neurotransmitter Agents have been mentioned in the context of this disorder. Affiliated tissues include brain, liver and skin, and related phenotypes are no effect and behavior/neurological

Wikipedia : ⁷⁵ Neurodegeneration is the progressive loss of structure or function of neurons, including death of... more...

Sources

Related Diseases for Cerebral Degeneration

Diseases related to Cerebral Degeneration via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 82)

#	Related Disease	Score	Top Affiliating Genes
1	leukodystrophy	30.7	POLR3B POLR3A PLP1 GJC2 GFAP EIF2B5
2	aceruloplasminemia	30.0	POLG PLA2G6 GFAP
3	mitochondrial dna depletion syndrome 4a	11.5
4	norrie disease	11.2
5	niemann-pick disease	11.1
6	brain small vessel disease 1 with or without ocular anomalies	11.1
7	brain small vessel disease 2	11.1
8	hydrocephalus	11.1
9	cerebrotendinous xanthomatosis	10.9
10	canavan disease	10.9
11	lipid storage disease	10.9
12	pelizaeus-merzbacher-like disease	10.5	PLP1 GJC2
13	inflammatory mfh	10.5	SERPINA3 GFAP
14	adrenomyeloneuropathy	10.5	SLC25A17 ABCD1
15	leukodystrophy, hypomyelinating, 4	10.5	PLP1 GJC2
16	binswanger's disease	10.5	PLP1 NOTCH3 GFAP
17	spastic paraplegia 2, x-linked	10.5	PLP1 GJC2
18	spinocerebellar degeneration	10.4	POLG ABCD1
19	demyelinating disease	10.4	PLP1 ABCD2 ABCD1
20	adrenoleukodystrophy	10.3	ABCD3 ABCD2 ABCD1
21	cortical blindness	10.3	POLG ABCD1
22	hereditary spastic paraplegia	10.3	PLP1 PLA2G6 L1CAM GJC2
23	hypomyelinating leukoencephalopathy	10.2	POLR3B POLR3A PLP1 GJC2
24	hypomyelinating leukodystrophy	10.2	POLR3B POLR3A PLP1 GJC2
25	granular cell tumor	10.1	SERPINA3 GFAP
26	x-linked recessive disease	10.0	SLC25A17 PLP1 ABCD3 ABCD2 ABCD1
27	amyotrophic lateral sclerosis 1	10.0
28	lateral sclerosis	10.0
29	encephalopathy	9.9
30	apraxia	9.8
31	polg-related disorders	9.8
32	cerebral atrophy	9.8
33	ataxia and polyneuropathy, adult-onset	9.8
34	microhydranencephaly	9.8
35	dementia	9.8
36	autosomal dominant cerebellar ataxia	9.8
37	fetal brain disruption sequence	9.8
38	alzheimer disease	9.7
39	mitochondrial complex iv deficiency	9.7
40	aging	9.7
41	yemenite deaf-blind hypopigmentation syndrome	9.7
42	aphasia	9.7
43	split hand-foot malformation	9.7
44	hemiplegia	9.7
45	bronchopneumonia	9.7
46	leukemia	9.7
47	hepatic coma	9.7
48	acute leukemia	9.7
49	hepatic encephalopathy	9.7
50	kluver-bucy syndrome	9.7

Comorbidity relations with Cerebral Degeneration via Phenotypic Disease Network (PDN): (show all 24)

Acute Cystitis	Alzheimer Disease
Bronchitis	Cerebral Atherosclerosis
Cerebrovascular Disease	Decubitus Ulcer
Deficiency Anemia	Encephalopathy
Epilepsy, Focal, with Speech Disorder and with or Without Mental Retardation	Familial Atrial Fibrillation
Generalized Atherosclerosis	Heart Disease
Hypertension, Essential	Hypothyroidism
Iron Deficiency Anemia	Major Depressive Disorder
Obstructive Hydrocephalus	Osteoporosis
Parkinson Disease, Late-Onset	Protein-Energy Malnutrition
Schizophreniform Disorder	Spinocerebellar Degeneration
Swallowing Disorders	Transient Cerebral Ischemia

Graphical network of the top 20 diseases related to Cerebral Degeneration:

Sources

Symptoms & Phenotypes for Cerebral Degeneration

GenomeRNAi Phenotypes related to Cerebral Degeneration according to GeneCards Suite gene sharing:

²⁶

#	Description	GenomeRNAi Source Accession	Score	Top Affiliating Genes
1	no effect	GR00402-S-1	9.92	ABCD1 ABCD2 ABCD3 ASPA DCAF8 EIF2B2

MGI Mouse Phenotypes related to Cerebral Degeneration:

⁴⁶

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	behavior/neurological	MP:0005386	10.06	ABCD1 ABCD2 ASPA EIF2B5 GFAP GJC2
2	hematopoietic system	MP:0005397	10	ABCD1 ABCD2 ASPA EIF2B2 EIF2B5 GJC2
3	immune system	MP:0005387	9.85	ABCD1 ABCD2 EIF2B5 GFAP GJC2 NOTCH3
4	nervous system	MP:0003631	9.77	ABCD1 ABCD2 ASPA EIF2B5 GFAP GJC2
5	vision/eye	MP:0005391	9.32	ABCD1 ASPA EIF2B5 GFAP GJC2 L1CAM

Sources

Drugs & Therapeutics for Cerebral Degeneration

Drugs for Cerebral Degeneration (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 20)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Galantamine

Approved

Phase 3

357-70-0

9651

Synonyms:

(-)-Galanthamine

(-)-GALANTHAMINE

(4aS,6R,8aS)-4a,5,9,10,11,12-Hexahydro-3-methoxy-11-methyl-6H-benzofuro(3a,3,2-ef)(2)benzazepin-6-ol

1551-02-6

1953-04-4

1dx6

1qti

357-70-0

4-27-00-02184 (Beilstein Handbook Reference)

736-79-8

AC1L1TIM

AC-20240

BIDD:GT0517

BPBio1_000480

BRD-K49481516-004-03-5

BRD-K49481516-004-04-3

BRN 0093736

BSPBio_000436

BSPBio_003416

C08526

CHEBI:42944

CHEMBL659

CID9651

D04292

DivK1c_000590

Galantamin

Galantamina

Galantamina [INN-Spanish]

Galantamine

Galantamine (USAN/INN)

Galantamine [USAN:INN]

Galantaminum

Galantaminum [INN-Latin]

galanthamine

Galanthamine

Galanthamine hydrobromide

Galanthaminum

GNT

HMS2089H03

HSDB 7361

IDI1_000590

InChI=1/C17H21NO3/c1-18-8-7-17-6-5-12(19)9-14(17)21-16-13(20-2)4-3-11(10-18)15(16)17/h3-6,12,14,19H,7-10H2,1-2H3/t12-,14-,17-/m0/s1

Jilkon

KBio1_000590

KBio2_001751

KBio2_004319

KBio2_006887

KBio3_002636

KBioGR_001417

KBioSS_001751

LS-71039

Lycoremin

Lycoremine

MolPort-002-521-885

NCGC00024731-02

NINDS_000590

Nivalin

Nivaline

NSC 100058

ortho McNeil neurologics brand OF galantamine

ortho-McNeil neurologics brand OF galantamine

Prestwick0_000588

Prestwick1_000588

Prestwick2_000588

Prestwick3_000588

Probes1_000055

Probes2_000395

Razadyne

Razadyne ER

Reminyl

Reminyl (TN)

SDCCGMLS-0066737.P001

SMP1_000131

SPBio_002655

Spectrum_001271

Spectrum3_001738

Spectrum4_000839

Spectrum5_001673

STOCK1N-46108

UNII-0D3Q044KCA

Neurotransmitter Agents

Phase 3

Cholinergic Agents

Phase 3

Peripheral Nervous System Agents

Phase 3

Cholinesterase Inhibitors

Phase 3

Nootropic Agents

Phase 3

Autonomic Agents

Phase 3

Montelukast

Approved

Phase 2

158966-92-8

5281040

Synonyms:

(R-(e))-1-(((1-(3-(2-(7-chloro-2-Quinolinyl)ethenyl)phenyl)-3-(2-(1-hydroxy-1-methylethyl)phenyl)propyl)thio)methyl)cyclopropaneacetate

(R-(e))-1-(((1-(3-(2-(7-chloro-2-Quinolinyl)ethenyl)phenyl)-3-(2-(1-hydroxy-1-methylethyl)phenyl)propyl)thio)methyl)cyclopropaneacetic acid

(R-(E))-1-(((1-(3-(2-(7-Chloro-2-quinolinyl)ethenyl)phenyl)-3-(2-(1-hydroxy-1-methylethyl)phenyl)propyl)thio)methyl)cyclopropaneacetic acid

{1-[({(1R)-1-{3-[(E)-2-(7-chloroquinolin-2-yl)ethenyl]phenyl}-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl}sulfanyl)methyl]cyclopropyl}acetic acid

1-((((1R)-1-(3-((1E)-2-(7-Chloro-2-quinolinyl)ethenyl)phenyl)-3-(2-(1-hydroxy-1-methylethyl)phenyl)propyl)thio)methyl)cyclopropaneacetic acid

1-[[[(1 R)-1-[3-[(1E)-2-(7-chloro-2-Quinolinyl)ethenyl] phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]sulfanyl]methyl]cyclopropaneacetate

1-[[[(1 R)-1-[3-[(1E)-2-(7-chloro-2-quinolinyl)ethenyl] phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]sulfanyl]methyl]cyclopropaneacetic acid

1-[[[(1 R)-1-[3-[(1E)-2-(7-chloro-2-Quinolinyl)ethenyl] phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]sulfanyl]methyl]cyclopropaneacetic acid

1-[[[(1 R)-1-[3-[(1E)-2-(7-chloro-2-Quinolinyl)ethenyl] phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]sulphanyl]methyl]cyclopropaneacetate

1-[[[(1 R)-1-[3-[(1E)-2-(7-chloro-2-Quinolinyl)ethenyl] phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]sulphanyl]methyl]cyclopropaneacetic acid

151767-02-1 (sodium)

158966-92-8

2-[1-[[(1R)-1-[3-[(E)-2-(7-chloroquinolin-2-yl)ethenyl]phenyl]-3-[2-(2-hydroxypropan-2-yl)phenyl]propyl]sulfanylmethyl]cyclopropyl]acetic acid

AC1NQXXW

Apxi toxin

BIDD:GT0394

Brondilat

Brondilat (TN)

C07482

C35H36ClNO3S

Cahill may roberts brand OF montelukast sodium

CHEBI:50730

CHEMBL787

CID5281040

D08229

DB00471

HMS2089D07

HSDB 7582

LS-173539

Merck brand OF montelukast sodium

Merck frosst brand OF montelukast sodium

Merck sharp and dohme brand OF montelukast sodium

MK 0476

MK-0476

Montair

montelukast

Montelukast

Montélukast

Montelukast (INN)

Montelukast [INN:BAN]

Montelukast sodium

Montelukastum

Singulair

Singular

sodium 1-(((1-(3-(2-(7-chloro-2-quinolinyl)ethenyl)phenyl)-3-(2-(1-hydroxy-1-methylethyl)phenyl)propyl)thio)methyl)cyclopropylacetate

Sodium 1-(((1-(3-(2-(7-chloro-2-quinolinyl)ethenyl)phenyl)-3-(2-(1-hydroxy-1-methylethyl)phenyl)propyl)thio)methyl)cyclopropylacetate

UNII-MHM278SD3E

Respiratory System Agents

Phase 2

Cytochrome P-450 Enzyme Inducers

Phase 2

Hormones

Phase 2

Hormone Antagonists

Phase 2

Anti-Asthmatic Agents

Phase 2

Leukotriene Antagonists

Phase 2

Hormones, Hormone Substitutes, and Hormone Antagonists

Phase 2

Triamcinolone

Approved, Vet_approved

124-94-7

31307

Synonyms:

(8S,9R,10S,11S,13S,14S,16R,17S)-9-fluoro-11,16,17-trihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one

11.Beta.,16.alpha.,17.alpha., 21-Tetrahydroxy-9.alpha.-fluoro-1,4-pregnadiene-3,20-dione

11.beta.,16.alpha.,17.alpha.,21-Tetrahydroxy-9.alpha.-fluoro-1,4-pregnadiene-3,20-dione

11b,16a,17a,21-Tetrahydroxy-9a-fluoro-1,4-pregnadiene-3,20-dione

11beta,16alpha,17alpha,21-Tetrahydroxy-9alpha-fluoro-1,4-pregnadiene-3,20-dione

11-beta,16-alpha,17-alpha,21-Tetrahydroxy-9-alpha-fluoro-1,4-pregnadiene-3,20-dione

11β,16α,17α,21-tetrahydroxy-9α-fluoro-1,4-pregnadiene-3,20-dione

124-94-7

4-08-00-03629 (Beilstein Handbook Reference)

83474-03-7

9.Alpha.-Fluoro-11.beta.,16.alpha.,17,21-tetrahy

9.alpha.-Fluoro-11.beta.,16.alpha.,17,21-tetrahydroxy-1,4-pregnadiene-3,20-dione

9.alpha.-Fluoro-11.beta.,16.alpha.,17,21-tetrahydroxypregna-1,4-diene-3,20-dione

9.Alpha.-Fluoro-11.beta.,16.alpha.,17.alpha., 21-tetrahydroxypregna-1,4-diene-3,20-d

9.alpha.-Fluoro-11.beta.,16.alpha.,17.alpha.,21-tetrahydroxypregna-1,4-diene-3,20-dione

9.alpha.-Fluoro-16.alpha.-hydroxyprednisolone

9a-fluoro-11b,16a,17,21-Tetrahydroxypregna-1,4-diene-3,20-dione

9a-fluoro-11b,16a,17a,21-Tetrahydroxypregna-1,4-diene-3,20-dione

9a-fluoro-16a-Hydroxyprednisolone

9alpha-Fluoro-11beta,16alpha,17,21-tetrahydroxy-1,4-pregnadiene-3,20-dione

9alpha-fluoro-11beta,16alpha,17,21-Tetrahydroxypregna-1,4-diene-3,20-dione

9alpha-Fluoro-11beta,16alpha,17,21-tetrahydroxypregna-1,4-diene-3,20-dione

9-alpha-Fluoro-11-beta,16-alpha,17,21-tetrahydroxypregna-1,4-diene-3,20-dione

9alpha-fluoro-11beta,16alpha,17alpha,21-Tetrahydroxypregna-1,4-diene-3,20-dione

9alpha-fluoro-16alpha-Hydroxyprednisolone

9alpha-Fluoro-16alpha-hydroxyprednisolone

9-alpha-Fluoro-16-alpha-hydroxyprednisolone

9-Fluoro-11,16,17,21-tetrahydroxypregna-1,4-diene-3,20-dione

9-fluoro-11b,16a,17,21-Tetrahydroxypregna-1,4-diene-3,20-dione

9-fluoro-11beta,16alpha,17,21-Tetrahydroxypregna-1,4-diene-3,20-dione

9-Fluoro-11beta,16alpha,17,21-tetrahydroxypregna-1,4-diene-3,20-dione

9-fluoro-11β,16α,17,21-tetrahydroxypregna-1,4-diene-3,20-dione

9α-fluoro-11β,16α,17,21-tetrahydroxypregna-1,4-diene-3,20-dione

9α-fluoro-11β,16α,17α,21-tetrahydroxypregna-1,4-diene-3,20-dione

9α-fluoro-16α-hydroxyprednisolone

AC1L1LDH

AC1Q5HJC

AC-2072

Adcortyl

Aristocort

Aristocort A

Aristocort Tablets

Aristogel

Aristospan

Azmacort

Bio-0662

BPBio1_000154

BRD-K77554836-001-03-3

BRN 2341955

BSPBio_000140

C21H27FO6

Celeste

CHEMBL1451

CID31307

Cinolone

Cinolone-T

CL 19823

D00385

D014221

DB00620

Delphicort

droxypregna-1,4-diene-3,20-dione

EINECS 204-718-7

EU-0101179

Fluoxiprednisolone

Fluoxyprednisolone

Flutex

Fougera

HMS1568G22

HMS2090D12

HSDB 3194

ione

Kenacort

Kenacort (TN)

Kenacort-A

Kenacort-Ag

Kenacort-AG

Kenalog

Kenalog in Orabase

Kenalog-10

Kenalog-40

Kenalog-H

Ledercort

Lopac0_001179

LS-698

MLS000028542

MLS001066543

MLS002695935

MolPort-002-528-981

Mycolog

Nasacort

Nasacort Aq

Nasacort Hfa

NCGC00021580-03

NCGC00021580-04

NCGC00021580-05

NCGC00021580-06

NCGC00021580-07

nchembio.2007.53-comp7

NCI60_000750

NSC 13397

NSC13397

Omcilon

Omicilon

Oracort

Oralone

Orion

Polcortolon

Pregna-1,4-diene-3,20-dio

Pregna-1,4-diene-3,20-dione, 9-fluoro-11,16,17,21-tetrahydroxy-, (11beta,16alpha)

Pregna-1,4-diene-3,20-dione, 9-fluoro-11beta,16alpha,17,21-tetrahydroxy- (8CI)

Prestwick_438

Prestwick0_000120

Prestwick1_000120

Prestwick2_000120

Prestwick3_000120

Rodinolone

S1933_Selleck

Sk-Triamcinolone

SK-Triamcinolone

SMP1_000300

SMR000058333

SPBio_002079

T6376_SIGMA

Tiamcinolonum

Tiamcinolonum [INN-Latin]

Triacet

Triacort

Triamcet

Triamcinalone

Triamcinlon

Triamcinolon

Triamcinolona

Triamcinolona [INN-Spanish]

triamcinolone

Triamcinolone

Triamcinolone (JP15/USP/INN)

TRIAMCINOLONE (SEE ALSO TRIAMCINOLONE ACETONIDE (76-25-5) AND TRIAMCINOLONE DIACETATE (67-78-7))

Triamcinolone [USAN:INN:BAN:JAN]

Triamcinolone acetonide

Triamcinolone diacetate

Triamcinolone hexacetonide

Triamcinolonum

Triamcinolonum [INN]

Triam-Tablinen

Triatex

Tricortale

Triderm

Trilone

Tri-Nasal

Tristoject

Trymex

UNII-1ZK20VI6TY

Vetalog

Volon

Volon A

WLN: L E5 B666 OV KU MUTJ A1 BF CQ E1 FV1Q FQ GQ

ZINC03882036

triamcinolone acetonide

Triamcinolone diacetate

Triamcinolone hexacetonide

Fluorodeoxyglucose F18

Interventional clinical trials:

#	Name	Status	NCT ID	Phase	Drugs
1	A European Multi-Center Study to Determine the Safety and Efficacy of Galanthamine Hydrobromide 40mg/Day (32 mg /Day GAL Base, Tid Dose Regimen) in Patients Diagnosed With Alzheimer-Type Dementia	Completed	NCT00338117	Phase 3	Galantamine hydrobromide
2	Effects of Montelukast Therapy on Alzheimer's Disease (EMERALD)	Not yet recruiting	NCT03991988	Phase 2	Montelukast;Placebo oral tablet
3	Magnetic Resonance Imaging Biomarkers in Amyotrophic Lateral Sclerosis	Completed	NCT02405182
4	The Motor Network in Essential Tremor: Mechanisms of Therapy	Recruiting	NCT02712515
5	Closing the Loop on Tremor: A Responsive Deep Brain Stimulator for the Treatment of Essential Tremor	Recruiting	NCT02649166
6	Application of Transcranial Alternating Current Stimulation for Modulation of Sleep and Cognitive Performance	Recruiting	NCT03112902
7	Novel MRI Biomarkers for Monitoring Disease Progression in ALS	Recruiting	NCT03362658
8	Coaching for Cognition in Alzheimer's (COCOA)	Recruiting	NCT03424200
9	Benefit of MRI and 18F-FDG PET Imaging in the Early Diagnosis of Alzheimer-like Dementia	Terminated	NCT01815112
10	Treating Sleep Wake Cycle Disturbances in Basal Ganglia Neurodegenerative Disorder Subjects With Ramelteon- A Double Blind, Placebo Controlled Trial	Withdrawn	NCT00907595		Ramelteon;Placebo

Search NIH Clinical Center for Cerebral Degeneration

Sources

Genetic Tests for Cerebral Degeneration

Sources

Anatomical Context for Cerebral Degeneration

MalaCards organs/tissues related to Cerebral Degeneration:

⁴¹

Brain, Liver, Skin, Testes, Cortex, Amygdala, Breast

Sources

Publications for Cerebral Degeneration

Articles related to Cerebral Degeneration:

(show top 50) (show all 177)

#	Title	Authors	PMID	Year
1	Quantifying changes on susceptibility weighted images in amyotrophic lateral sclerosis using MRI texture analysis. ³⁸	Johns SLM...Kalra S	31025885	2019
2	Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Effects of PF-06751979, a Potent and Selective Oral BACE1 Inhibitor: Results from Phase I Studies in Healthy Adults and Healthy Older Subjects. ³⁸	Qiu R...Chen D	31424395	2019
3	Reliability of 3D texture analysis: A multicenter MRI study of the brain. ³⁸	Ta D...Kalra S	31423714	2019
4	Management of concussion in soccer. ³⁸	Hubertus V...Vajkoczy P	30687899	2019
5	Alabama Brief Cognitive Screener: Utility of a New Cognitive Screening Instrument in a Memory Disorders Clinic. ³⁸	Love MCN...Geldmacher DS	30896091	2019
6	A study of the effects of 8-week acupuncture treatment on patients with Parkinson's disease. ³⁸	Yeo S...Lim S	30557997	2018
7	Evaluating the cerebral correlates of survival in amyotrophic lateral sclerosis. ³⁸	Ishaque A...Kalra S	30480029	2018
8	Texture Analysis to Detect Cerebral Degeneration in Amyotrophic Lateral Sclerosis. ³⁸	Ishaque A...Kalra S	30234470	2018
9	The role of Alu-derived RNAs in Alzheimer's and other neurodegenerative conditions. ³⁸	Polesskaya O...Myakishev-Rempel M	29685192	2018
10	Interaction between the AAA ATPase p97/VCP and a concealed UBX domain in the copper transporter ATP7A is associated with motor neuron degeneration. ³⁸	Yi L...Kaler SG	29599289	2018
11	A strategy to find novel candidate anti-Alzheimer's disease drugs by constructing interaction networks between drug targets and natural compounds in medical plants. ³⁸	Chen BW...Huang JF	29770277	2018
12	Type-I interferons in Parkinson's disease: innate inflammatory response drives fate of neurons in model of degenerative brain disorder: An editorial comment on 'Type-I interferons mediate the neuroinflammatory response and neurotoxicity induced by rotenone'. ³⁸	Kanninen KM...White AR	28332229	2017
13	Widespread temporo-occipital lobe dysfunction in amyotrophic lateral sclerosis. ³⁸	Loewe K...Schoenfeld MA	28067298	2017
14	Abnormal Brain Connectivity Spectrum Disorders Following Thimerosal Administration: A Prospective Longitudinal Case-Control Assessment of Medical Records in the Vaccine Safety Datalink. ³⁸	Geier DA...Geier MR	28539852	2017
15	Clinicopathological characteristics of patients with amyotrophic lateral sclerosis resulting in a totally locked-in state (communication Stage V). ³⁸	Hayashi K...Isozaki E	27716404	2016
16	Dispersion entropy for the analysis of resting-state MEG regularity in Alzheimer's disease. ³⁸	Azami H...Escudero J	28269715	2016
17	Crosstalk between 6-OHDA-induced autophagy and apoptosis in PC12 cells is mediated by phosphorylation of Raf-1/ERK1/2. ³⁸	Li J...Wu B	29442034	2016
18	Split Hand / Foot Malformation Syndrome with Cerebral Degeneration. ³⁸	Mahavar SK...Sharma R	27730782	2016
19	High Content, Multi-Parameter Analyses in Buccal Cells to Identify Alzheimer's Disease. ³⁸	Francois M...The Australian Imaging Biomarkers And Lifestyle Study Research Group	26975368	2016
20	Cerebral Degeneration in Amyotrophic Lateral Sclerosis Revealed by 3-Dimensional Texture Analysis. ³⁸	Maani R...Kalra S	27064416	2016
21	Thimerosal exposure and increased risk for diagnosed tic disorder in the United States: a case-control study. ³⁸	Geier DA...Geier MR	27486363	2015
22	Early detection of widespread progressive brain injury after cardiac arrest: a single case DTI and post-mortem histology study. ³⁸	Gerdes JS...Deppe M	24633135	2014
23	[Genetic aspects of Alzheimer's disease (Review)]. ³⁸	El Kadmiri N...Nadifi S	24035416	2013
24	Improved prediction of Alzheimer's disease with longitudinal white matter/gray matter contrast changes. ³⁸	Grydeland H...Fjell AM	22674625	2013
25	Specific needs of dopamine neurons for stimulation in order to survive: implication for Parkinson disease. ³⁸	Michel PP...Hirsch EC	23699175	2013
26	Mentalizing in preclinical Huntington's disease: an fMRI study using cartoon picture stories. ³⁸	Saft C...Brune M	23179063	2013
27	Mitochondrial aldehyde dehydrogenase-2 activation prevents β-amyloid-induced endothelial cell dysfunction and restores angiogenesis. ³⁸	Solito R...Donnini S	23447675	2013
28	Phenotypic spectrum of COL4A1 mutations: porencephaly to schizencephaly. ³⁸	Yoneda Y...Saitsu H	23225343	2013
29	The response of cerebral cortex to haemorrhagic damage: experimental evidence from a penetrating injury model. ³⁸	Purushothuman S...Stone J	23555765	2013
30	Disease-specific expression of the serotonin-receptor 5-HT(2C) in natural killer cells in Alzheimer's dementia. ³⁸	Martins LC...Reis HJ	22766135	2012
31	Acupuncture stimulation on GB34 activates neural responses associated with Parkinson's disease. ³⁸	Yeo S...Kim SH	22943145	2012
32	Fractional anisotropy of water diffusion in cerebral white matter across the lifespan. ³⁸	Kochunov P...Glahn DC	20122755	2012
33	De novo and inherited mutations in COL4A2, encoding the type IV collagen α2 chain cause porencephaly. ³⁸	Yoneda Y...Saitsu H	22209246	2012
34	Intranasal treatment of neurodegenerative diseases and stroke. ³⁸	Gomez D...Toth CC	22202044	2012
35	Transient improvement of acquired hepatocerebral degeneration with parkinsonian symptoms after failed liver transplant: case report and literature review. ³⁸	Chen Y...Yoshida EM	22142042	2011
36	The multiple phenotypes of corticobasal syndrome and corticobasal degeneration: implications for further study. ³⁸	Boeve BF	21853287	2011
37	Association between environmental exposure to pesticides and neurodegenerative diseases. ³⁸	Parron T...Alarcon R	21601587	2011
38	The extrinsic and intrinsic apoptotic pathways are involved in manganese toxicity in rat astrocytoma C6 cells. ³⁸	Alaimo A...Kotler ML	21704098	2011
39	Punica granatum protects against oxidative stress in PC12 cells and oxidative stress-induced Alzheimer's symptoms in mice. ³⁸	Choi SJ...Shin DH	21631359	2011
40	"Theory of mind" is impaired in Huntington's disease. ³⁸	Brune M...Saft C	21384426	2011
41	Visual signs and symptoms of progressive supranuclear palsy. ³⁸	Armstrong RA	20629667	2011
42	Xanthene food dye, as a modulator of Alzheimer's disease amyloid-beta peptide aggregation and the associated impaired neuronal cell function. ³⁸	Wong HE...Kwon I	21998691	2011
43	Impulsive behavior and associated clinical variables in Parkinson's disease. ³⁸	Abosch A...Grant JE	21300194	2011
44	Progression of brain atrophy and cognitive decline in diabetes mellitus: a 3-year follow-up. ³⁸	van Elderen SG...van der Grond J	20837967	2010
45	Proteomic analysis of aging brain in SAMP10 mouse: a model of age-related cerebral degeneration. ³⁸	Furukawa A...Shimada A	20471994	2010
46	Amygdala size reduction is associated with memory deficits in complicated hereditary spastic paraparesis: an MRI study. ³⁸	Pinkhardt EH...Kassubek J	20664204	2010
47	Are astrocytes the missing link between lack of brain aspartoacylase activity and the spongiform leukodystrophy in Canavan disease? ³⁸	Baslow MH...Guilfoyle DN	19319678	2009
48	The role of stress and anxiety in the onset of familial Creutzfeldt-Jakob Disease (CJD): review. ³⁸	Gigi A	19051123	2009
49	Methodology for discovery of Alzheimer's disease blood-based biomarkers. ³⁸	Maes OC...Wang E	19366883	2009
50	Novel anti-Alzheimer's dimer Bis(7)-cognitin: cellular and molecular mechanisms of neuroprotection through multiple targets. ³⁸	Li W...Han Y	19110209	2009

Sources

Genes for Cerebral Degeneration

Genes related to Cerebral Degeneration (0 elite genes):

(show all 29)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence
1	NOTCH3	Notch Receptor 3	Protein Coding	19.56	DISEASES inferred ¹⁵
2	ABCD1	ATP Binding Cassette Subfamily D Member 1	Protein Coding	18.89	DISEASES inferred ¹⁵
3	PLP1	Proteolipid Protein 1	Protein Coding	18.65	DISEASES inferred ¹⁵
4	DCAF8	DDB1 And CUL4 Associated Factor 8	Protein Coding	18.44	DISEASES inferred ¹⁵ ¹⁵
5	ASPA	Aspartoacylase	Protein Coding	18.2	DISEASES inferred ¹⁵
6	SERPINA3	Serpin Family A Member 3	Protein Coding	17.53	DISEASES inferred ¹⁵ ¹⁵
7	PLA2G6	Phospholipase A2 Group VI	Protein Coding	17.51	DISEASES inferred ¹⁵
8	POLG	DNA Polymerase Gamma, Catalytic Subunit	Protein Coding	17.33	DISEASES inferred ¹⁵
9	EIF2B5	Eukaryotic Translation Initiation Factor 2B Subunit Epsilon	Protein Coding	17.25	DISEASES inferred ¹⁵
10	GJC2	Gap Junction Protein Gamma 2	Protein Coding	17.22	DISEASES inferred ¹⁵
11	L1CAM	L1 Cell Adhesion Molecule	Protein Coding	17.21	DISEASES inferred ¹⁵
12	ABCD3	ATP Binding Cassette Subfamily D Member 3	Protein Coding	17.19	DISEASES inferred ¹⁵
13	ZIC3	Zic Family Member 3	Protein Coding	17.18	DISEASES inferred ¹⁵
14	GFAP	Glial Fibrillary Acidic Protein	Protein Coding	17.13	DISEASES inferred ¹⁵
15	EIF2B2	Eukaryotic Translation Initiation Factor 2B Subunit Beta	Protein Coding	17.09	DISEASES inferred ¹⁵
16	HEPACAM	Hepatic And Glial Cell Adhesion Molecule	Protein Coding	16.98	DISEASES inferred ¹⁵
17	POLR3B	RNA Polymerase III Subunit B	Protein Coding	16.9	DISEASES inferred ¹⁵
18	POLR3A	RNA Polymerase III Subunit A	Protein Coding	16.82	DISEASES inferred ¹⁵
19	SLC25A17	Solute Carrier Family 25 Member 17	Protein Coding	7.59	DISEASES inferred ¹⁵
20	ABCD2	ATP Binding Cassette Subfamily D Member 2	Protein Coding	7.46	DISEASES inferred ¹⁵
21	EIF2B1	Eukaryotic Translation Initiation Factor 2B Subunit Alpha	Protein Coding	6.78	DISEASES inferred ¹⁵
22	HTRA1	HtrA Serine Peptidase 1	Protein Coding	6.71	DISEASES inferred ¹⁵
23	LMNB1	Lamin B1	Protein Coding	6.63	DISEASES inferred ¹⁵
24	ABCD4	ATP Binding Cassette Subfamily D Member 4	Protein Coding	6.58	DISEASES inferred ¹⁵
25	HYDIN	HYDIN Axonemal Central Pair Apparatus Protein	Protein Coding	6.49	DISEASES inferred ¹⁵
26	ASPRV1	Aspartic Peptidase Retroviral Like 1	Protein Coding	6.47	DISEASES inferred ¹⁵
27	FA2H	Fatty Acid 2-Hydroxylase	Protein Coding	6.46	DISEASES inferred ¹⁵
28	AARS2	Alanyl-TRNA Synthetase 2, Mitochondrial	Protein Coding	6.43	DISEASES inferred ¹⁵
29	DLG4	Discs Large MAGUK Scaffold Protein 4	Protein Coding	6.38	GeneCards inferred via : Publications (show sections)

Sources

Variations for Cerebral Degeneration

Sources

Expression for Cerebral Degeneration

Search GEO for disease gene expression data for Cerebral Degeneration.

Sources

Pathways for Cerebral Degeneration

Pathways related to Cerebral Degeneration according to GeneCards Suite gene sharing:

#	Super pathways	Score	Top Affiliating Genes
1	Peroxisome ³⁷	10.84	SLC25A17 ABCD3 ABCD2 ABCD1

Sources

GO Terms for Cerebral Degeneration

Cellular components related to Cerebral Degeneration according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	myelin sheath	GO:0043209	9.4	PLP1 GJC2
2	RNA polymerase III complex	GO:0005666	9.37	POLR3B POLR3A
3	integral component of peroxisomal membrane	GO:0005779	9.26	SLC25A17 ABCD1
4	peroxisome	GO:0005777	9.26	SLC25A17 ABCD3 ABCD2 ABCD1
5	eukaryotic translation initiation factor 2B complex	GO:0005851	9.16	EIF2B5 EIF2B2
6	peroxisomal membrane	GO:0005778	8.92	SLC25A17 ABCD3 ABCD2 ABCD1
7	cytosol	GO:0005829	10.1	POLR3B POLR3A PLA2G6 NOTCH3 GFAP EIF2B5

Biological processes related to Cerebral Degeneration according to GeneCards Suite gene sharing:

(show all 17)

#	Name	GO ID	Score	Top Affiliating Genes
1	transmembrane transport	GO:0055085	9.92	SLC25A17 GJC2 ABCD3 ABCD2 ABCD1
2	myelination	GO:0042552	9.61	PLP1 EIF2B5 EIF2B2
3	positive regulation of interferon-beta production	GO:0032728	9.57	POLR3B POLR3A
4	oligodendrocyte development	GO:0014003	9.56	EIF2B5 EIF2B2
5	peroxisome organization	GO:0007031	9.55	ABCD3 ABCD1
6	negative regulation of cytokine production involved in inflammatory response	GO:1900016	9.54	ABCD1 ABCD2
7	negative regulation of reactive oxygen species biosynthetic process	GO:1903427	9.51	ABCD2 ABCD1
8	central nervous system myelination	GO:0022010	9.49	PLP1 ASPA
9	positive regulation of fatty acid beta-oxidation	GO:0032000	9.48	ABCD2 ABCD1
10	neuron projection maintenance	GO:1990535	9.46	ABCD2 ABCD1
11	astrocyte development	GO:0014002	9.43	PLP1 GFAP EIF2B5
12	myelin maintenance	GO:0043217	9.4	ABCD2 ABCD1
13	positive regulation of unsaturated fatty acid biosynthetic process	GO:2001280	9.37	ABCD2 ABCD1
14	peroxisomal long-chain fatty acid import	GO:0015910	9.32	ABCD3 ABCD1
15	fatty acid beta-oxidation	GO:0006635	9.26	SLC25A17 ABCD3 ABCD2 ABCD1
16	axon development	GO:0061564	9.16	PLP1 L1CAM
17	very long-chain fatty acid catabolic process	GO:0042760	8.8	ABCD3 ABCD2 ABCD1

Molecular functions related to Cerebral Degeneration according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	nucleotidyltransferase activity	GO:0016779	9.33	POLR3B POLR3A POLG
2	RNA polymerase III activity	GO:0001056	9.26	POLR3B POLR3A
3	ATPase activity, coupled to transmembrane movement of substances	GO:0042626	9.13	ABCD3 ABCD2 ABCD1
4	long-chain fatty acid transporter activity	GO:0005324	8.62	ABCD3 ABCD1

Sources

Sources for Cerebral Degeneration

¹ BioSystems

² BitterDB

³ CDC

⁴ Cell Signaling Technology

⁵ ClinicalTrials

⁶ ClinVar

⁷ CNVD

⁸ Cochrane Library

⁹ Cosmic

¹⁰ dbSNP

¹¹ DGIdb

¹² Disease Ontology

¹³ diseasecard

¹⁴ DiseaseEnhancer

¹⁵ DISEASES

¹⁶ DrugBank

¹⁷ EFO

¹⁸ ExPASy

¹⁹ FMA

²⁰ GeneAnalytics

²¹ GeneCards

²² GeneGo (Thomson Reuters)

²³ GeneHancer via GeneCards

²⁴ GeneReviews

²⁵ Genetics Home Reference

²⁶ GenomeRNAi

²⁷ GEO DataSets

²⁸ GO

²⁹ GTR

³⁰ HGMD

³¹ HMDB

³² HPO

³³ ICD10

³⁴ ICD10 via Orphanet

³⁵ ICD9CM

³⁶ IUPHAR

³⁷ KEGG

³⁸ LifeMap

³⁹ LncRNADisease

⁴⁰ LOVD

⁴¹ MalaCards

⁴² MedGen

⁴³ MedlinePlus

⁴⁴ MeSH

⁴⁵ MESH via Orphanet

⁴⁶ MGI

⁴⁷ miR2Disease

⁴⁸ NCBI Bookshelf

⁴⁹ NCI

⁵⁰ NCIt

⁵¹ NDF-RT

⁵² NIH Clinical Center

⁵³ NIH Rare Diseases

⁵⁴ NINDS

⁵⁵ Novoseek

⁵⁶ Novus Biologicals

⁵⁷ OMIM

⁵⁸ OMIM via Orphanet

⁵⁹ Orphanet

⁶⁰ PathCards

⁶¹ PharmGKB

⁶² PubMed

⁶³ PubMed Health

⁶⁴ QIAGEN

⁶⁵ R&D Systems

⁶⁶ Reactome

⁶⁷ Sino Biological

⁶⁸ SNOMED-CT

⁶⁹ SNOMED-CT via HPO

⁷⁰ TGDB

⁷¹ Tocris

⁷² UMLS

⁷³ UMLS via Orphanet

⁷⁴ UniProtKB/Swiss-Prot

⁷⁵ Wikipedia